UPCC 15217: A Pivotal Trial of ARQ 087 in Subjects with FGFR2 Gene Fusion Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma
Brief description of study
The main purpose of this study is to find out if the study drug ARQ 087 is safe and effective to use in patients with intrahepatic cholangiocarcinoma.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Cholangiocarcinoma
-
Age: Between 18 Years - 99 Years
-
Gender: All
Updated on
30 Jan 2020.
Study ID: 827501
